ARTICLE SUMMARY:
The medtech -focused venture firm has Chinese roots, but a close-to-home US investment strategy.
William Dai launched ShangBay Capital in 2015, after a career working as chief financial officer for some of China’s largest medical device companies, including the Chinese operations of Boston Scientific and Chinese medtech giant MicroPort. “I’ve spent the past 25 years doing a lot of deals and mergers and acquisitions work,” he says.
After working for large corporations, Dai started small when he launched his investment firm: ShangBay’s first fund raised $30 million, and based on the success of that fund, it raised a second of $55 million in early 2019. It has since raised a third fund of around $90 million. In total, ShangBay has raised nearly $200 million and made investments in more than 50 companies, nearly, but not all medtechs, and has seen five exits.
